NO328958B1 - Anvendelse av ET-743 eller en pegylert liposomal form av doxorubicin, kombinasjon av disse, medisinsk kit samt farmasoytisk sammensetning - Google Patents
Anvendelse av ET-743 eller en pegylert liposomal form av doxorubicin, kombinasjon av disse, medisinsk kit samt farmasoytisk sammensetning Download PDFInfo
- Publication number
- NO328958B1 NO328958B1 NO20072543A NO20072543A NO328958B1 NO 328958 B1 NO328958 B1 NO 328958B1 NO 20072543 A NO20072543 A NO 20072543A NO 20072543 A NO20072543 A NO 20072543A NO 328958 B1 NO328958 B1 NO 328958B1
- Authority
- NO
- Norway
- Prior art keywords
- pld
- effective therapeutic
- combination
- administered
- therapeutic amount
- Prior art date
Links
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 title claims abstract description 115
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 title claims abstract description 113
- 229960000977 trabectedin Drugs 0.000 title claims abstract description 112
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 title claims abstract description 28
- 229960004679 doxorubicin Drugs 0.000 title claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 28
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 201000011510 cancer Diseases 0.000 claims abstract description 18
- 229940045799 anthracyclines and related substance Drugs 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 23
- 238000001802 infusion Methods 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 18
- 206010039491 Sarcoma Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 238000010253 intravenous injection Methods 0.000 claims description 5
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 3
- 238000002648 combination therapy Methods 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 5
- 231100000682 maximum tolerated dose Toxicity 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 206010048610 Cardiotoxicity Diseases 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 231100000259 cardiotoxicity Toxicity 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010019851 Hepatotoxicity Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 230000007686 hepatotoxicity Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000003167 cholangitis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 231100000334 hepatotoxic Toxicity 0.000 description 2
- 230000003082 hepatotoxic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 241000798369 Ecteinascidia turbinata Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000187081 Streptomyces peucetius Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 231100000052 myelotoxic Toxicity 0.000 description 1
- 230000002556 myelotoxic effect Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229940004212 yondelis Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62216304P | 2004-10-26 | 2004-10-26 | |
| PCT/GB2005/050189 WO2006046080A2 (en) | 2004-10-26 | 2005-10-26 | Pegylated liposomal doxorubicin in combination with ecteinescidin 743 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20072543L NO20072543L (no) | 2007-07-13 |
| NO328958B1 true NO328958B1 (no) | 2010-06-28 |
Family
ID=36096124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072543A NO328958B1 (no) | 2004-10-26 | 2007-05-16 | Anvendelse av ET-743 eller en pegylert liposomal form av doxorubicin, kombinasjon av disse, medisinsk kit samt farmasoytisk sammensetning |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20090117176A1 (enExample) |
| EP (1) | EP1827500B1 (enExample) |
| JP (2) | JP4554684B2 (enExample) |
| KR (1) | KR101287918B1 (enExample) |
| CN (1) | CN101119750B (enExample) |
| AT (1) | ATE430586T1 (enExample) |
| AU (1) | AU2005298364B2 (enExample) |
| BR (1) | BRPI0518250A2 (enExample) |
| CA (1) | CA2582452C (enExample) |
| CY (1) | CY1110329T1 (enExample) |
| DE (1) | DE602005014380D1 (enExample) |
| DK (1) | DK1827500T3 (enExample) |
| ES (1) | ES2326825T3 (enExample) |
| HR (1) | HRP20090345T1 (enExample) |
| IL (1) | IL182352A (enExample) |
| MX (1) | MX2007004744A (enExample) |
| NO (1) | NO328958B1 (enExample) |
| NZ (1) | NZ554765A (enExample) |
| PL (1) | PL1827500T3 (enExample) |
| PT (1) | PT1827500E (enExample) |
| RS (1) | RS50822B (enExample) |
| RU (1) | RU2359700C2 (enExample) |
| SI (1) | SI1827500T1 (enExample) |
| UA (1) | UA87877C2 (enExample) |
| WO (1) | WO2006046080A2 (enExample) |
| ZA (1) | ZA200703396B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164077A (en) | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| US20040108086A1 (en) * | 2000-11-06 | 2004-06-10 | Naoto Takahashi | Effective antitumor treatments |
| GB0117402D0 (en) * | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
| GB0202544D0 (en) | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
| SI1689404T1 (sl) | 2003-11-13 | 2009-02-28 | Pharma Mar Sau | Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka |
| US20080255132A1 (en) * | 2003-11-14 | 2008-10-16 | Eric Rowinsky | Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer |
| RS50510B (sr) | 2004-10-29 | 2010-03-02 | Pharma Mar S.A., Sociedad Unipersonal | Formulacije koje sadrže ekteinascidin i disaharid |
| GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| US8444963B2 (en) | 2006-06-19 | 2013-05-21 | John Hopkins University | Tumor specific delivery of therapeutic agents via liposomase |
| US20100267732A1 (en) * | 2007-10-19 | 2010-10-21 | Pharma Mar, S.A. | Prognostic Molecular Markers for ET-743 Treatment |
| US11110108B2 (en) | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| RU2657835C1 (ru) * | 2017-11-28 | 2018-06-15 | Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" | Способ получения системы для доставки противоопухолевого препарата в клетки опухоли |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149804A (en) * | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
| US5256663A (en) * | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
| US5089273A (en) * | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
| DE3635711A1 (de) * | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| US5478932A (en) * | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
| US20040059112A1 (en) * | 1994-02-18 | 2004-03-25 | Rinehart Kenneth L. | Ecteinascidins |
| GB9508195D0 (en) * | 1995-04-20 | 1995-06-07 | Univ British Columbia | Novel biologically active compounds and compositions,their use and derivation |
| US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| US5721362A (en) * | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
| US5985876A (en) * | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
| CZ301083B6 (cs) * | 1998-04-06 | 2009-11-04 | The Board Of Trustees Of The University Of Illinois | Ekteinascidinová sloucenina, farmaceutický prostredek ji obsahující a její použití |
| US6124292A (en) * | 1998-09-30 | 2000-09-26 | President And Fellows Of Harvard College | Synthetic analogs of ecteinascidin-743 |
| MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| MY130271A (en) * | 1999-05-14 | 2007-06-29 | Pharma Mar Sa | Hemisynthetic method and new compounds |
| US20020028237A1 (en) * | 2000-04-20 | 2002-03-07 | Colbern Gail T. | Method for reducing toxicity of a cytotoxic agent |
| US7247892B2 (en) * | 2000-04-24 | 2007-07-24 | Taylor Geoff W | Imaging array utilizing thyristor-based pixel elements |
| US7420051B2 (en) * | 2000-05-15 | 2008-09-02 | Pharma Mar, S.A. | Synthetic process for the manufacture of an ecteinaschidin compound |
| MXPA02011319A (es) * | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| CA2418320A1 (en) * | 2000-08-11 | 2002-02-21 | City Of Hope | The anti-neoplastic agent et-743 inhibits trans activation by sxr |
| ATE314084T1 (de) * | 2000-10-31 | 2006-01-15 | Pharma Mar Sa | Kahalalid f formulierung |
| US20040108086A1 (en) * | 2000-11-06 | 2004-06-10 | Naoto Takahashi | Effective antitumor treatments |
| HUP0303466A3 (en) * | 2001-03-06 | 2005-02-28 | Bristol Myers Squibb Company P | Method and dosage form for treating tumors by administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin |
| EP1401396A4 (en) * | 2001-06-15 | 2009-08-05 | Cornerstone Pharmaceuticals | PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIONS WITH NANOPARTICLES FOR THE TREATMENT OF TARGET TISSUE AND CELLS |
| KR20050038578A (ko) * | 2001-10-19 | 2005-04-27 | 파르마 마르, 에스.에이. | 항종양성 화합물의 암치료에 있어서의 향상된 용도 |
| US20040019027A1 (en) * | 2002-04-12 | 2004-01-29 | Barry Forman | Method of treating cerebrotendinous xanthomatosis |
| AU2003253954A1 (en) * | 2002-07-16 | 2004-02-02 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Support bra for ultrasonic breast scanner |
| GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
| GB0324201D0 (en) * | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
| SI1689404T1 (sl) * | 2003-11-13 | 2009-02-28 | Pharma Mar Sau | Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka |
| GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
| US20080255132A1 (en) * | 2003-11-14 | 2008-10-16 | Eric Rowinsky | Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer |
| US20050129752A1 (en) * | 2003-12-15 | 2005-06-16 | Tty Biopharm Limited Company | Use and manufacturing process for liposomal doxorubicin pharmaceutical composition |
| US20080293725A1 (en) * | 2004-07-09 | 2008-11-27 | Rafael Rosell Costa | Prognostic Molecular Markers |
| RS50510B (sr) * | 2004-10-29 | 2010-03-02 | Pharma Mar S.A., Sociedad Unipersonal | Formulacije koje sadrže ekteinascidin i disaharid |
| WO2007062413A2 (en) * | 2005-11-25 | 2007-05-31 | University Of Medicine And Dentistry Of New Jersey | Use of parp-1 inhibitors |
| US20080075772A1 (en) * | 2006-04-13 | 2008-03-27 | Lawrence Solomon | Pharmaceutical compositions having novel scoring patterns and methods of using those compositions |
| WO2007134203A2 (en) * | 2006-05-12 | 2007-11-22 | Pharma Mar, S.A. | Anticancer treatments with a combination of docetaxel and ecteinascidin |
-
2005
- 2005-10-26 HR HR20090345T patent/HRP20090345T1/xx unknown
- 2005-10-26 PL PL05803151T patent/PL1827500T3/pl unknown
- 2005-10-26 CA CA2582452A patent/CA2582452C/en not_active Expired - Lifetime
- 2005-10-26 KR KR1020077009355A patent/KR101287918B1/ko not_active Expired - Lifetime
- 2005-10-26 MX MX2007004744A patent/MX2007004744A/es active IP Right Grant
- 2005-10-26 DE DE602005014380T patent/DE602005014380D1/de not_active Expired - Lifetime
- 2005-10-26 RU RU2007119545/14A patent/RU2359700C2/ru active
- 2005-10-26 UA UAA200705818A patent/UA87877C2/ru unknown
- 2005-10-26 PT PT05803151T patent/PT1827500E/pt unknown
- 2005-10-26 ES ES05803151T patent/ES2326825T3/es not_active Expired - Lifetime
- 2005-10-26 JP JP2007538524A patent/JP4554684B2/ja not_active Expired - Lifetime
- 2005-10-26 CN CN2005800369316A patent/CN101119750B/zh not_active Expired - Lifetime
- 2005-10-26 NZ NZ554765A patent/NZ554765A/en not_active IP Right Cessation
- 2005-10-26 WO PCT/GB2005/050189 patent/WO2006046080A2/en not_active Ceased
- 2005-10-26 RS RSP-2009/0311A patent/RS50822B/sr unknown
- 2005-10-26 SI SI200530688T patent/SI1827500T1/sl unknown
- 2005-10-26 EP EP05803151A patent/EP1827500B1/en not_active Revoked
- 2005-10-26 AT AT05803151T patent/ATE430586T1/de active
- 2005-10-26 US US11/577,790 patent/US20090117176A1/en not_active Abandoned
- 2005-10-26 AU AU2005298364A patent/AU2005298364B2/en not_active Expired
- 2005-10-26 BR BRPI0518250-6A patent/BRPI0518250A2/pt not_active Application Discontinuation
- 2005-10-26 DK DK05803151T patent/DK1827500T3/da active
-
2007
- 2007-04-01 IL IL182352A patent/IL182352A/en active IP Right Grant
- 2007-04-25 ZA ZA200703396A patent/ZA200703396B/xx unknown
- 2007-05-16 NO NO20072543A patent/NO328958B1/no unknown
-
2009
- 2009-08-03 CY CY20091100818T patent/CY1110329T1/el unknown
- 2009-09-24 JP JP2009219607A patent/JP2009292850A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO328958B1 (no) | Anvendelse av ET-743 eller en pegylert liposomal form av doxorubicin, kombinasjon av disse, medisinsk kit samt farmasoytisk sammensetning | |
| AU2007240264B2 (en) | Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines | |
| US6403563B1 (en) | Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate | |
| US9107925B2 (en) | Sodium channel blocker for treatment of loss of superficial sensitivity | |
| KR20010102364A (ko) | 상승작용성 항종양 조성물 | |
| KR20100031759A (ko) | 흑색종의 치료 | |
| US9937261B2 (en) | Combination therapy comprising a liposomal prodrug of mitomycin C and radiotherapy | |
| US20180296529A1 (en) | Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin c | |
| KR20010072228A (ko) | 위장 독성이 감소된 캠프토테신 유도체의 용도 | |
| EP2268287B1 (en) | Dosage regimens of an antitumor agent comprising deoxycytidine derivative | |
| KR20120104574A (ko) | 티보자닙과 템시롤리무스의 조합물 | |
| US20040266704A1 (en) | Method comprising irinotecan for treatment of breast cancer | |
| HK1107766B (en) | Pegylated liposomal doxorubicin in combination with ecteinescidin 743 | |
| JP2019131508A (ja) | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 | |
| US20050215604A1 (en) | Combination therapies with epothilones and carboplatin | |
| CA2381078A1 (en) | Method of potentiating chemotherapy and treating solid tumors | |
| Fountain | DRUG PREPARATIONS OF REDUCED TOXCITY 75 Inventors | |
| EP1599210A1 (en) | A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent | |
| ZA200607806B (en) | Combination therapies with epothilones and carboplatin |